Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease
Autore:
Minea, D; Varga, I; Falup-Pecurariu, C; de Mey, C; Retzow, A; Althaus, M;
Indirizzi:
Desitin Arzneimittel GMBH, D-22335 Hamburg, Germany Desitin Arzneimittel GMBH Hamburg Germany D-22335 22335 Hamburg, Germany Appl Clin Pharmacol Serv, Meinz Kastel, Germany Appl Clin Pharmacol Serv Meinz Kastel Germany rv, Meinz Kastel, Germany Univ Transsilvania, Dept Neurol, Brasov, Romania Univ Transsilvania Brasov Romania ilvania, Dept Neurol, Brasov, Romania
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 4, volume: 24, anno: 2001,
pagine: 235 - 238
SICI:
0362-5664(200107/08)24:4<235:IOTDAA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; BROMOCRIPTINE; BIOAVAILABILITY; MULTICENTER;
Keywords:
alpha-dihydroergocryptine; levodopa; pharmacokinetics; interaction; Parkinson's disease;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Althaus, M Desitin Arzneimittel GMBH, Weg Beim Jager 214, D-22335 Hamburg,Germany Desitin Arzneimittel GMBH Weg Beim Jager 214 Hamburg Germany D-22335
Citazione:
D. Minea et al., "Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease", CLIN NEUROP, 24(4), 2001, pp. 235-238

Abstract

This study investigated whether chronic coadministration of alpha -dihydroergocryptine (DHEC) altered the plasma pharmacokinetics of individualized treatments with levodopa in 12 patients with Parkinson's disease. Steady-state pharmacokinetics of plasma levodopa (L-Dopa) under combined treatment were compared with those under treatment with L-Dopa alone. There was no evidence of increased exposure to L-Dopa caused by concomitant treatment with DHEC. In contrast, additional treatment with DHEC reduced the overall exposure to L-Dopa (17.5% reduction in area under the curve; 95% Cl: 23%-6%). This effect was small but statistically significant for the area under the plasma concentration-time curve, whereas t(max) (time of maximum plasma concentration) and peak-to-trough fluctuation were not affected. C-max (maximum plasma concentration), on average, was reduced to a similar extent (-14.5%; 95% Cl: 38% to -17%), albeit not significantly. The magnitude of the interaction does not suggest changing the current clinical practice of up-titrating DHEC and subsequently adapting L-Dopa to the individual needs of patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 22:38:10